NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

Mary B. Daly(Fox Chase Cancer Center), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Matthew B. Yurgelun(Dana-Farber Brigham Cancer Center), Michael P. Berry(St. Jude Children's Research Hospital), Saundra S. Buys(University of Utah), Patricia Dickson(Barnes-Jewish Hospital), Susan M. Domchek(University of Pennsylvania), Ahmed Elkhanany(University of Colorado Cancer Center), Susan Friedman(Facing Our Risk of Cancer Empowered), Judy E. Garber(Dana-Farber Brigham Cancer Center), Michael Goggins(Comprehensive Blood & Cancer Center), Mollie L. Hutton, Seema Khan(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Catherine Klein(University of Colorado Cancer Center), Wendy Kohlmann(University of Utah), Allison W. Kurian(Cancer Institute (WIA)), Christine Laronga(Moffitt Cancer Center), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Julie Mak(UCSF Helen Diller Family Comprehensive Cancer Center), Carolyn S. Menendez(Cancer Institute (WIA)), Sofía D. Merajver(University of Michigan), Barbara S. Norquist(Seattle Cancer Care Alliance), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Tuya Pal(Breast Cancer Research Foundation), Holly J. Pederson(Cleveland Clinic), Gwen Reiser(Susan Thompson Buffett Foundation), Kristen M. Shannon(Massachusetts General Hospital), Kala Visvanathan(Comprehensive Blood & Cancer Center), Jeffrey N. Weitzel(City Of Hope National Medical Center), Myra Wick, Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Mary A. Dwyer(National Comprehensive Cancer Network), Susan Darlow(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
April 1, 2020
Cited by 504Open Access
Full Text

Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.


Related Papers

No related papers found

Powered by citation graph analysis